Ignacio Melero

Dendritic cells in cancer immunology and immunotherapy

Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As suc...

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Advances in immunotherapy for hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 co...

Cytokines in clinical cancer immunotherapy

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

ClinicalTrials.gov Identifier: NCT01658878.

Table 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

<p>Characteristics of patients treated with GEN1046</p>

Table 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

<p>Treatment-related AEs reported in >2 patients treated with GEN1046 (<i>n</i> = 61)</p>

Figure 3 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

<p>GEN1046 promotes TIL expansion from patient-derived tumor tissue. Tumor tissues resected from patients with NSCLC were cut into pieces of 1 to 2 mm<sup>3</sup&...

Figure 4 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

<p>Pharmacokinetics and pharmacodynamics of GEN1046 in patients with advanced solid tumors. <b>A,</b> Mean plasma concentration of GEN1046 during the first two...

Figure 5 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

<p>GEN1046 antitumor efficacy in patients with advanced solid tumors. <b>A,</b> Waterfall plot of best relative percent change from baseline in tumor size. &lt...

Figure 2 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

<p>GEN1046 therapeutic efficacy and antitumor immune responses in MC38-hPD-L1 tumor–bearing hPD-L1/h4-1BB dKI mice. <b>A,</b> MC38-hPD-L1 cells (1 × 10<sup&...

Figure 1 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

<p>GEN1046 induces dose-dependent, conditional T-cell proliferation and cytokine production and enhances antigen-specific T-cell–mediated cytotoxicity <i>in vitro&lt...